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Abstract
The Wnt/b-catenin pathway plays a crucial role in the pathogenesis of various human cancers. In multiple myeloma (MM),
aberrant auto-and/or paracrine activation of canonical Wnt signaling promotes proliferation and dissemination, while
overexpression of the Wnt inhibitor Dickkopf1 (DKK1) by MM cells contributes to osteolytic bone disease by inhibiting
osteoblast differentiation. Since DKK1 itself is a target of TCF/b-catenin mediated transcription, these findings suggest that
DKK1 is part of a negative feedback loop in MM and may act as a tumor suppressor. In line with this hypothesis, we show
here that DKK1 expression is low or undetectable in a subset of patients with advanced MM as well as in MM cell lines. This
absence of DKK1 is correlated with enhanced Wnt pathway activation, evidenced by nuclear accumulation of b-catenin,
which in turn can be antagonized by restoring DKK1 expression. Analysis of the DKK1 promoter revealed CpG island
methylation in several MM cell lines as well as in MM cells from patients with advanced MM. Moreover, demethylation of the
DKK1 promoter restores DKK1 expression, which results in inhibition of b-catenin/TCF-mediated gene transcription in MM
lines. Taken together, our data identify aberrant methylation of the DKK1 promoter as a cause of DKK1 silencing in advanced
stage MM, which may play an important role in the progression of MM by unleashing Wnt signaling.
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Introduction
Multiple myeloma (MM), one of the most common hematolog-
ical malignancies in adults, is characterized by a clonal expansion of
malignant plasma cells in the bone marrow, associated with
suppression of normal hematopoiesis, renal failure, and osteolytic
bone lesions [1], [2]. These bone lesions have been shown to be the
result of uncoupled or imbalanced bone remodeling with decreased
formation and increased resorption of bone tissue, due to impaired
osteoblast differentiation and aberrant osteoclast activation [3].
Recent studies have identified canonical Wnt signaling as a key
signal pathway in both normal bone homeostasis and in the
pathogenesis of MM bone disease [4–6].
The canonical Wnt/b-catenin signaling pathway plays a central
role in modulating the delicate balance between stemness and
differentiation in several adult stem cell niches, including the
intestinal crypt and the hematopoietic stem cell niche in the bone
marrow [7–9]. Wnt genes encode a family of 19 secreted
glycoproteins, which promiscuously interact with several Frizzled
(FRZ) receptors and the low-density lipoprotein receptor-related
protein 5/6 (LRP5/6). The key event in the Wnt signaling
pathway is the stabilization of b-catenin. Signaling by Wnt
proteins results in inhibition of glycogen synthase kinase-3b
(GSK3b) activity and dissociation of the adenomatous polyposis
coli (APC)/axin complex, resulting in accumulation of b-catenin,
which translocates to the nucleus. Here, b-catenin interacts with T
cell factor (TCF) transcription factors to drive transcription of
target genes [10]. The Wnt pathway is regulated by a large
number of antagonists, including the secreted frizzled-related
proteins (sFRPs) and the Dickkopf (DKK) family proteins. These
two classes of antagonists either act by direct binding to the Wnt
ligands (the sFRPs) or by interacting with the LPR5/6 coreceptors,
preventing binding of the Wnt proteins to the FRZ/LRP receptor
complex (the DKKs) [11].
Recent studies indicate that the Wnt signaling plays at least two
distinct roles in the pathogenesis of MM. On the one hand, studies
by our own laboratory [12] as well as by the Anderson laboratory
[13] have demonstrated that MMs can display aberrant activation
of the canonical Wnt signaling pathway. This Wnt pathway
activation presumably results from auto- and/or paracrine
stimulation by Wnts, and promotes tumor proliferation and
dissemination [12], [13]. On the other hand, as first shown by
Tian and colleagues [6], MMs overexpress and secrete the Wnt
signaling inhibitor Dickkopf-1 (DKK1), which contributes to
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17]. Similar to DKK1, secretion of the Wnt inhibitor sFRP2 by
MM cells may also promote myeloma bone disease [5]. Since both
DKK1 and sFRP2 are established targets of TCF/b-catenin-
mediated transcription [18–20], these findings suggests the
presence of a negative feedback loop in MM in which DKK1
and sFRP2 act as potential tumor suppressors. In line with this
hypothesis, we show here that DKK1 expression is often low or
undetectable in advanced myeloma and is absent in MM cell lines,
which are generally derived from advanced extramedullary
myeloma. This silencing of DKK1 is caused by methylation of
the DKK1 promoter and unleashes b-catenin/TCF mediated
transcription.
Materials and Methods
Ethics Statements
The study involving human biopsy samples was conducted in
accordance with the Declaration of Helsinki and approved by the
local ethics committee of The University of Amsterdam, AIEC
(Algemene Instellingsgebonden Ethische Commissie). Patients
gave written informed consent for the sample collection.
Case selection and classification
A panel of BM biopsy specimen from 41 MM and 7 MGUS
patients, obtained at clinical diagnosis, was selected from the files
of the Department of Pathology, Academic Medical Center,
University of Amsterdam, Amsterdam, The Netherlands. All
patients were staged according to the Salmon–Durie system. For
statistical analysis patients at stage I and II disease were grouped
together (n=16) and classified as early MM, whereas patients with
stage III disease (n=25) were classified as having advanced MM.
Microarray analysis
For the analysis of expression of Wnt family members in MM
patients, expression data publically available and deposited in the
NIH Gene Expression Omnibus (GEO National Center for
Biotechnology Information [NCBI], http://www.ncbi.nlm.nih.
gov/geo/ were used. These concerned the U133 Plus2.0
affymetrix oligonucleotide microarray data from 559 newly
diagnosed MM patients included in total therapy 2/3 (TT2,
TT3), provided by the University of Arkansas for Medical
Sciences, GSE2658 [21].
Immunohistochemistry/Immunocytochemistry
Immunohistochemical staining was performed on formalin-
fixed, plastic-embedded bone marrow sections as described
previously [22]. Sections were deplastified in acetone, after which
endogenous peroxidase was blocked with a 0.3% solution of H2O2
in methanol and followed by antigen retrieval for 10 minutes in
TRIS/EDTA buffer (respectively 10 mM/1 mM) pH 9.0 at
100uC. After blocking with serum free blocker (DAKO, Carpin-
teria, CA), the slides were either incubated for one hour at room
temperature with anti-CD138 (IQP-153 IQ Products, Groningen,
The Netherlands) or overnight at 4uC with anti-DKK1 (Abcam,
Cambridge, MA), or anti-b-catenin (clone 14 BD Biosciences,
Erembodegem, Belgium). For CD138 and b-catenin, binding of
the antibody was visualized using the PowerVision plus detection
system (Immunovision Technologies, Duiven, The Netherlands)
and 3, 3-diaminobenzidine (Sigma-Aldrich, St Louis, MO).
Whereas binding of the DKK1-antibody was visualized with a
biotinylated rabbit anti-goat antibody, followed by horseradish
peroxidase (HRP)-conjugated streptavidin (DAKO) and DAB
+
(DAKO). The sections were counterstained with hematoxylin
(Merck, Darmstadt, Germany), washed and subsequently dehy-
drated through graded alcohol, cleared in xylene, and cover-
slipped. Immunocytochemical staining was performed on forma-
lin-fixed cells. Briefly, slides were incubated for 30 minutes with
PBS 0.3% Triton X-100 followed by blocking with serum free
blocker (DAKO, Carpinteria, CA), the slides were then incubated
overnight at 4uC with anti-DKK1 (goat polyclonal R@D). Binding
of the DKK1-antibody was visualized with a biotinylated rabbit
anti-goat antibody, followed by horseradish peroxidase (HRP)-
conjugated streptavidin (DAKO) and 3-amino-9-ethyl carbazole
(AEC).
The biopsies were analyzed for DKK1 and b-catenin expression
by two independent observers (RWJG and STP). DKK1
expression was scored in three semi-quantitative categories, i.e.,
low (0–25%), intermediate (25–75%) and high (75–100%), with
the percentages indicating the number of DKK1 positive MM
plasma cells. For b-catenin expression the intensity of nuclear
staining was scored as negative/low, intermediate or high. For
statistical analysis, the cases scored as negative/low and interme-
diate were grouped together as low b-catenin.
Methylation analysis
Genomic DNA was extracted and purified from MM bone
marrow suspensions and cell lines using DNAzol (Invitrogen Life
technologies, Breda, The Netherlands) according to the manufac-
turer’s protocol. The extracted DNA was modified by treatment
with sodium bisulfite using the EpiTect Bisulfite Kit (Qiagen,
Hilden, Germany). The methylation status of the DKK1 gene was
assessed using both methylation specific PCR (MSP) and bisulfate
sequencing, as described by Aquilera et al. [23].
Cell culture and demethylation treatment
MM cell lines L363, UM-1, OPM-1, RPMI 8226, and PC-3
were cultured in RPMI medium 1640 (Invitrogen Life technolo-
gies) containing 10% clone I serum (HyClone), 100 units/ml
penicillin, and 100 mg/ml streptomycin. XG-1 and LME-1 cell
lines were cultured in IMDM medium (Invitrogen Life technol-
ogies) supplemented with transferrin (20 mg/ml) and b-mercapto-
ethanol (50 mM). For XG-1, medium was additionally supple-
mented with IL-6 (500 pg/m). 293T cells were cultured in DMEM
medium containing 10% clone I serum (HyClone), 100 units/ml
penicillin, and 100 mg/ml streptomycin. The PC-3 cell line was
kindly provided by Christopher Hall. L-cells and Wnt3a-
producing L-cells (L-306.72 Mouse L fibroblasts, stably transfected
with Wnt3a) were cultured in DMEM medium (Invitrogen Life
technologies) containing 10% clone I serum (HyClone), 100 units/
ml penicillin, and 100 mg/ml streptomycin. Conditioned medium
was harvested from 95% confluent flasks every 72 h and stored at
4uC. 5-aza-29-deoxycytidine (5-aza-CdR Sigma-Aldrich) treat-
ment was performed for 72 h at a final concentration of 5 mM,
after which they were harvested and lysed in Trizol (Invitrogen
Life technologies).
RT-PCR
Total RNA was isolated using Trizol according to the
manufacturer’s protocol (Invitrogen Life technologies). The RNA
was further purified using iso-propanol precipitation and was
concentrated using the RNeasy MinElute Cleanup kit (Qiagen).
The quantity of total RNA was measured using a NanoDrop ND-
1000 Spectrophotometer (NanoDrop Technologies, Wilmington,
DE). 5 mg of total RNA was used for cDNA synthesis as described
previously. The PCR mixture contained: 100 ng of cDNA, 16
PCR Rxn buffer (Invitrogen Life technologies), 0.2 mmol/L
dNTP, 2 mmol/L MgCl2, 0.2 mmol/L of each primer, and 1 U
DKK1 Methylation in Advanced MM
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conditions were: denaturing at 95uC for 5 minutes, followed by 30
cycles of 30 s at 95uC, 30 s at 65uC (DKK1), 55uC( b-actin) and
30 s at 72uC. The reaction was completed for 10 minutes at 72uC.
Primers used were: DKK1 forward (59–GATCATAGCACCTTG-
GATGGG–39) DKK1 reverse (59–CAGTCTGATGACCGG–39)
b-actin forward (59–GGATGCAGAAGGAGATCACTG–39) b-
actin reverse (59–TCCACACGGAGTACTTG–39). All primers
were manufactured by Sigma-Aldrich (Haverhill, UK).
Western blot analysis
Conditioned medium was directly lysed in sample buffer,
separated by SDS/10% PAGE, and blotted. Primary goat anti-
DKK1 antibody (R@D) was detected by a horseradish peroxidase-
conjugated swine anti-goat antibody, followed by detection using
Lumi-Light PLUS western blotting substrate (Roche). Protein was
harvested from MM cell lines, fractionated using a nuclear/cytosol
fractionation kit (BioVision), separated by 10% SDS-polyacryl-
amide gel electrophoresis and subsequently blotted. The following
antibodies were used: b-catenin (clone 14 BD Biosciences,
Erembodegem, Belgium), b-tubulin (SantaCruz Biotechnologies),
and histone H2B (Imgenex). Primary antibodies were detected by
HRP-conjugated secondary antibodies, followed by detection
using Lumi-Light PLUS western blotting substrate (Roche).
Retroviral vector production and transduction of MM cell
lines
The LZRS-pBMN-DKK1-IRES-eGFP retroviral vector encod-
ing DKK1 and eGFP gene was generated by inserting the DKK1
gene from pcDNA3.1 into the BamHI and XhoI sites of LZRS-
pBMN-IRES-eGFP vector (S-001-AB provided by Dr. G. Nolan).
The amphotropic Phoenix packaging cell line was transfected
either with LZRS-pBMN-IRES-eGFP or LZRS-pBMN-DKK1-
IRES-eGFP by the use of Fugene (Roche). The selection of
transfected cells was performed with puromycine. Virus was
harvested from the packaging cell lines when 95% of the cells were
eGFP-positive as analyzed by fluorescence activated cell sorting
(FACS). Transduction of MM cell lines was done by 16 h of
incubation with virus supernatant in the presence of 10 mg/ml
retronectin (Takara Biomedicals, Shiga, Japan). 2 days after the
transduction eGFP positive cells were analyzed and sorted by
FACS. The transduced MM cells were expanded and examined
regularly for eGFP and DKK1 expression. The expression of
DKK1 protein was determined in conditioned medium by western
blot analysis.
Luciferase assay
MM cells (10 mln) were transfected with TOPFLASH reporter
construct (5 ug) and pRL-TK (1 ug) in 500 ul serum-free medium.
Treatment with Wnt3a conditioned medium or L-cell conditioned
medium was initiated 24 h upon transfection and subsequently
maintained for 24 h. Next, MM cells were lysed in 100 ul passive
lysis buffer (Promega) and firefly luciferase activity and Renilla
luciferase activity were measured using the dual luciferase assay kit
(Promega) following the manufacturers instruction. Renilla lucifer-
ase activity served as an internal control for transfection efficiency.
Statistical analysis
The chi-square (x
2) test was used to test the correlation between
the DKK1 expression and the stage of disease, the relation
between expression of nuclear b-catenin and the stage of disease
and the correlation between expression of DKK1 and nuclear
b-catenin.
Results
Wnt signaling activation is associated with advanced
stage MM
Previous studies have demonstrated that the malignant plasma
cells in MM can display Wnt pathway activation. Since no
mutations in Wnt pathway components were detected, this
activation is presumably caused by auto- and/or paracrine
stimulation by Wnt ligands secreted in the bone marrow
microenvironment. [12], [13]. In support of a ligand-dependent
activation scenario, analysis of gene expression profiling data of
the malignant plasma cells of 345 MM patients (http://www.ncbi.
nlm.nih.gov/geo/ accession number GSE2658) revealed frequent
(co-)expression of various Frizzleds (e.g. Fzd 1, 3, 6, 7 and 8) and
the co-receptor LRP6 (LRP5 could not be studied because of
defective probe sets), as well as various Wnts (e.g. 4, 5A, 5B 6, 10A
and 16). Moreover, 51% of the primary MMs co-express the co-
receptor LRP6 with at least one of the Frizzled genes and one of
the Wnt genes (Table S1). Hence, in the majority of MM patients
the malignant plasma cells appear to be well equipped to evoke
autocrine activation of the Wnt pathway. Furthermore, Wnt
ligands are produced by bone marrow stromal cells [12], [24],
[25], which may cause paracrine Wnt pathway activation.
To explore whether MM cells localized within the bone marrow
microenvironment indeed display evidence of active Wnt
signaling, we analyzed a panel of MM bone marrow biopsies for
nuclear expression of b-catenin, a key feature of active canonical
Wnt signaling [22], [26]. The panel consisted of 41 MM and 7
MGUS biopsies patients all biopsies were obtained at first
diagnosis. Immunohistochemical studies revealed strong b-catenin
staining in the malignant plasma cells of 34% of the MM patients
(Figure 1 A–B). Interestingly, as shown in Figure 1B, b-catenin
expression was significantly correlated with disease stage: nuclear
b-catenin was present in none of the MGUS patients, 19% of the
stage I/II patients, and 44% of the patients with advanced MM
(p,0.05). These findings imply the presence of active Wnt
signaling in BM-cocalized MM cells and show that this is
associated with advanced stage MM.
Absence of DKK1 expression unleashes Wnt pathway
activation in MM
Since stimulation by (autocrine and/or paracrine) Wnt ligands
appears to underly Wnt pathway activation in MM, loss of
secreted Wnt pathway antagonists like DKKs and sFRPs could
have a major impact on the pathogenesis of MM. In particular
DKK1, which binds to LRP5/6 thereby preventing activation of
the pathway by Wnt ligands, might act as a potent negative
regulator as it has been shown to be overexpressed by MM cells
[18–20]. To gain insight into the expression of the DKK1 protein
in primary MM samples, we studied DKK1 expression in the above
described panel of BM biopsies. DKK1 was detected in most
(81%) of the biopsies. However, in a significant proportion
expression was either restricted to a subfraction of the malignant
plasma cells or was entirely lost (Figure 1 A, C). In contrast to
expression of b-catenin, DKK1 expression was negatively
correlated with disease stage: whereas all MGUS patients and
the majority of early (stage I/II) MM patients demonstrated high
DKK1 expression, DKK1 was either partially or completely
absent in 68% of the patients with advanced MM (p,0.05)
(Figure 1C). Furthermore, DKK1 protein expression was not
detected in any of the studied MM cell lines (Figure 1D). Direct
comparison between the level of DKK1 and nuclear b-catenin
expression in individual patients indeed revealed a significant
inverse correlation between these parameters (p,0.05) (Figure 1E).
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and MM stage with a low or undetectable levels of DKK1 in a
subset of patients with advanced stage MM (p,0.05), and an
inverse relation to nuclear b-catenin expression.
The above findings suggest that silencing of DKK1 may unleash
activation of the canonical Wnt pathway by Wnt ligands, leading
to increased levels of nuclear b-catenin in MM cells of patients
with advanced disease. To explore whether DKK1 expression by
MM cells can indeed control the response of MM cells to ligand-
induced Wnt pathway activation, we restored the DKK1
expression in the MM cell lines OPM-1 and UM-1 by retroviral
transduction (Figure 2A). OPM-1 and UM-1 lack mutations in
Wnt pathway components and co-express Frizzleds, the co-
receptor LRP6, and Wnts, and have been reported to display
constitutively active b-catenin/TCF-dependent transcription [12],
[27], [28]. As shown in Figure 2B, introduction of DKK1
expression in OPM-1 and UM-1 cells leads to reduced Wnt3a
induced and baseline b-catenin levels. Furthermore, it results in a
significant inhibition of ligand-induced TCF-mediated transcrip-
tion (Figure 2C). These findings suggest that DKK1 expression by
MM cells could indeed restrain the response of these cells to Wnt
ligands expressed in the BM microenvironment.
DKK1 promoter hypermethylation in MM cell lines and
primary tumors
To further analyze the absence of DKK1 expression in MM, we
examined MM cell lines for DKK1 mRNA expression. In MM cell
lines, which all lack detectable levels of DKK1 protein (Figure 1D
Figure 1. The relation between the Wnt pathway activation and the loss of DKK1 expression during MM progression. (A)
Representative pictures of immunohistochemical staining of a multiple myeloma patient displaying either high DKK-1 and low b-catenin expression
(upper panel) or with DKK-1 loss and increased nuclear b-catenin localization (lower panel). Immunohistochemical stainings are shown for CD138 (left
column), b-catenin (middle column) and DKK1 (right column). (B) Nuclear b-catenin expression in relation to multiple myeloma progression (n=48,
p,0.05). (C) DKK-1 expression in relation to multiple myeloma progression (p,0.05). (D) Representative pictures of immunocytochemical staining of
multiple myeloma cell lines with goat polyclonal anti-DKK1 antibody (magnification: 4006). Prostate cancer cell line (PC-3) was used as positive
control (PC) for the DKK-1 staining. (E) Relation between the loss of DKK-1 expression and nuclear localization of b-catenin (p.0.05). A significant
correlation (p,0.05) between expression of nuclear b-catenin and DKK-1 was observed in the two extreme groups identified based on b-catenin
expression. * indicates p value,0.05.
doi:10.1371/journal.pone.0030359.g001
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1, RPMI 8226 and OPM-1), or weakly expressed (XG-1, L363
and LME-1) in comparison to the DKK1 expression in the (positive
control) prostate cancer cell line PC-3 (Figure 3A) [29].
Since it has been reported that DKK1 is a target for epigenetic
inactivation by CpG island promoter hypermethylation in several
forms of cancer [23], [30–33], we hypothesized that epigenetic
silencing could also be responsible for the lack of DKK1 in
primary MM cells and cell lines. Hence, we studied the DKK1
promoter region, including the CpG island encompassing the
transcriptional start site for methylation using a methylation
specific PCR (MSP) and a bisulphate-sequencing PCR (BSP)
(Figure 3B). DNA isolated from the colon cancer cell lines HT-29
and DLD-1, previously reported to be unmethylated and
methylated, respectively [23], was used to validate our experi-
mental set-up (Figure 3C).
Combined MSP and BSP analysis revealed that four of the
6 MM cell lines tested, i.e., L363, LME-1, UM-1, and OPM-1,
showed hypermethylation of the DKK1 promoter, while XG-1 and
RMPI8226 were unmethylated (Figure 3 D–E). Notably, the BSP
analysis of OPM-1 revealed a methylation pattern that was not
detected by the MSP primers, thus showing the necessity of using
both techniques to adequately perform methylation studies.
Interestingly, in the L363 cell line four out of ten sequenced
clones displayed extensive CpG methylation, suggesting that either
a subset of the cells show methylation or that there is partial
Figure 2. DKK1 expression represses Wnt pathway activation in MM. (A) MM cell lines OPM-1 and UM-1 were transduced with either the
LZRS-pBMN-IRES-eGFP (control) or the LZRS-pBMN-DKK1-IRES-eGFP (DKK1) virus. Conditioned medium of sorted, transduced cells was harvested and
immunoblotted using a goat polyclonal antibody against DKK1. Representative immunoblot confirms the expression of DKK1 in the conditioned
medium of LZRS-pBMN-DKK1-IRES-eGFP transduced cells. b-actin is shown as internal control for equal cell number. (B) Cytoplasmic and nuclear
proteins were prepared from the LZRS-pBMN-IRES-eGFP (control) or the LZRS-pBMN-DKK1-IRES-eGFP (DKK1) MM cells, stimulated for 24h with Wnt3a
conditioned medium (+). As a control, L-cells conditioned medium was applied (2).To assess b-catenin accumulation, nuclear and cytoplasmic cells
lysate was immunoblotted by using a monoclonal anti-b-catenin antibody. The bottom part of the blot was stained with b-tubulin and Histone H2B
as controls for cytoplasmic and nuclear proteins, respectively. (C) LZRS-pBMN-IRES-eGFP (control) or the LZRS-pBMN-DKK1-IRES-eGFP (DKK1) cells
were transfected with TOPFLASH reporter and renilla contruct. 24 hours upon transfection cells were treated with L-cells conditioned medium (2)o r
Wnt3a conditioned medium (+).The relative light units value of LZRS-pBMN-IRES-eGFP cells treated with L-cells conditioned medium was normalized
to 1. The mean 6 SD of representative experiment performed in triplicate is shown. * indicates p value,0.05 *** indicates p value,0.001. by
student’s t test.
doi:10.1371/journal.pone.0030359.g002
DKK1 Methylation in Advanced MM
PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e30359DKK1 Methylation in Advanced MM
PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e30359monoallelic methylation within individual cells. The lack of DKK1
expression despite the absence of promoter methylation in
RPMI8226 cells indicates either the mere lack of transcriptional
activation or an alternative mechanism of DKK1 silencing.
Since DKK1 expression appears to be decreased in MM cells
isolated from patients with advanced stage MM, we next
investigated the DKK1 promoter associated CpG island in the
bone marrow mononuclear cells (BM-MNC) of patients with MM
and compared this to BM-MNC from healthy donors. All 12
patients had stage III disease. The DKK1 promoter was
hypermethylated in 33% of the primary MM specimens studied,
as determined by BSP (Figure S2) and MSP analysis (Figure 4). In
accordance with a previous study [32], none of the healthy donor
BM samples tested displayed methylation of the DKK1 promoter
(data not shown).
Promoter methylation silences DKK1 expression
To assess whether DKK1 promoter methylation indeed plays a
causative role in the transcriptional silencing of DKK1 in MM, we
investigated whether DKK1 expression could be restored or
enhanced by treatment with the demethylating agent 5-aza-2-
deoxycytidine. Analysis by BSP of the genomic DNA isolated from
OPM-1 and UM-1 cells, which combine a lack of DKK1
expression with hypermethylation of its promoter (Figures 1D
and Figure 3), confirmed that treatment results in a decrease in
methylation of the DKK1 promoter (Figure 5A). Importantly,
treatment of these cell lines results in restoration of DKK1
expression (Figure 5B). In addition, in LME-1, a cell line with a
hypermethylated DKK1 promoter and low DKK1 expression, DKK1
expression was increased upon 5-aza-2-deoxycytidine treatment.
As expected, treatment of XG-1 and RPMI8226, the two cell lines
that lack methylation of the DKK1 promoter, did not affect the
expression (Figure 5B). Taken together, these data establish a
direct role for CpG island methylation in epigenetic silencing of
DKK1 expression in MM.
Discussion
We have previously demonstrated that the Wnt pathway, which
is essential for normal T and B cell development [8], [34] and
plays a key role in the development of several types of cancer [35],
[36], is aberrantly activated in MM and can promote MM tumor
growth [12]. Subsequent studies have confirmed the oncogenic
potential of the Wnt pathway in MM by demonstrating that
targeting the Wnt pathway by drugs or siRNAs leads to inhibition
of MM growth [12], [13], [37–39]. In addition, by knocking down
b-catenin, Dutta-Simmons et al. revealed new potential Wnt/b-
catenin transcriptional targets involved in various aspects of cell-
cycle progression, such as CDC25 A/B, cyclins, cyclin-dependent
kinases, and AurKA/B. Among the genes significantly downreg-
ulated upon b-catenin knock down, a significant proportion had
LEF/TCF4 (GCTTTGT/A) binding sites in their promoters,
identifying them as putative direct Wnt target genes [13].
Although the exact cause(s) of aberrant Wnt pathway activation
in MM has not yet been established, the absence of detectable Wnt
pathway mutations [12] as well as the (over)expression of Wnt
ligands in the BM microenvironment by both stromal cells and by
the MM cells themselves [12], [28], (and table S1), suggests a key
role for autocrine and/or paracrine stimulation. As a consequence,
loss of secreted Wnt pathway antagonists like DKKs and sFRPs
could have a major impact on the pathogenesis of MM. Indeed,
we observed that whereas the DKK1 protein is strongly expressed
in most primary MMs, the expression of this Wnt antagonist is
down-regulated or even completely absent in a subgroup of
advanced (stage III) MMs (Figure 1A, C). In addition, the DKK1
Figure 4. Analysis of DKK1 promoter methylation in MM bone marrow samples. Methylation specific PCR of the CpG island of the DKK1
promoter region in the bone marrow samples of twelve patients with multiple myeloma (P1–P12), HT-29 and DLD-1 colon cell lines were used as
unmethylated (U_DNA) and methylated (M_DNA) control respectively. DNA bands in lanes labeled with U and M indicate PCR products amplified
with primers recognizing unmethylated and methylated promoter sequences respectively.
doi:10.1371/journal.pone.0030359.g004
Figure 3. DKK1 promoter methylation in MM cell lines. (A) Total RNA was isolated and RT–PCR analyses were performed with the specific
primers indicated. Complementary DNA from prostate cancer cell line (PC-3) was used as positive control (PC) for DKK1 expression. The b-actin
expression was used as a loading control. (B) Schematic representation of the promoter area analyzed for DKK1, containing a CpG island. White
arrows indicate the positions of primers used for bisulfite sequencing, and black arrows indicate the positions of primers used for methylation specific
PCR. Each of the CpG dinucleotides is presented as open circle. (C) Upper panel. Representation of bisulfite genomic sequencing results of 5 clones of
the DKK1 promoter region in HT-29 and DLD-1 colon cell lines used as unmethylated (U_DNA) and methylated (M_DNA) control, respectively. The
amplified 326 bp product corresponds to the DKK1 promoter region from 2193 to +122. In total, 18 CpG dinucleotides (CpGs) within the CpG island
were analyzed and are represented as open and closed circles, which indicate unmethylated and methylated CpG sites, respectively. Lower panel.
Electropherograms of bisulfite modified DNA from DKK1 CpG island in HT-29 (U_DNA) and DLD-1 (M_DNA) cells. (D) Methylation specific PCR of the
CpG island of the DKK1 promoter region in MM cell lines. DNA bands in lanes labeled with U indicate PCR products amplified with primers
recognizing unmethylated promoter sequences, whereas DNA bands in lanes labeled with M represent amplified products with primers designed for
the methylated template. (E) Bisulfite sequencing analysis of the the DKK1 promoter region in multiple myeloma cell lines, open circles indicating
unmethylated CpG sites, and closed circles representing methylated CpG sites. Percentages indicate the fraction of methylated CpG dinucleotides of
the total CpG sites analyzed.
doi:10.1371/journal.pone.0030359.g003
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ultimate, microenvironment independent, phase of MM tumor
progression and are almost invariably derived from extramedul-
lary MMs (Figure 1D and Figure S1).
Interestingly, low or undetectable of DKK1 protein expression
in BM samples of MM patients was correlated with an increased
nuclear expression of b-catenin, a hallmark of canonical Wnt
signaling (Figure 1E). DKK1 is a major Wnt pathway antagonist
which acts by interfering with the binding of Wnt ligands to the
LRP5/6 coreceptor [40]. Importantly, the DKK1 gene itself is a
direct target of b-catenin/TCF-mediated transcription [18–20],
and DKK1 has been implicated in the feed-back regulation of Wnt
signaling in several biological systems [41–43]. Consistent with a
tumor suppressor function, DKK1 silencing during tumor progres-
sion has been reported in several types of cancer [23], [30–33].
Our observation, that DKK1 levels can be low or undetectable in
advanced MM and that restoration of its expression inhibits b-
catenin/TCF transcriptional activity (Figure 2C), suggests that
silencing of DKK1 may contribute to activation of the canonical
Wnt pathway during MM progression.
Like loss of function mutations, aberrant methylation of the
promoter of tumor suppressor genes can provide a selective
advantage toneoplastic cells[44–48].WeidentifiedDKK1 promoter
hypermethylationasamechanismunderlying theabsenceofDKK1
expression in MM (Figure 3, 4, 5). In four of the 6 MM cell lines
tested, i.e., L363, LME-1, UM-1, and OPM-1, we showed
hypermethylation of the DKK1 promoter (Figure 3). The CpG
island analyzed encompasses the first exon of the DKK1 gene, which
encodes the transcriptional and translational start sites as well as a
significant part of the region upstream of the coding sequence, an
organization characteristic of genes targeted by epigenetic silencing
[46]. Indeed, this CpG island has previously been implicated in
DKK1 silencing in several types of cancer, including colorectal
cancer, gastric cancer, breast cancer, medulloblastoma and
leukemia [23], [30–33]. Importantly, the promoter methylation
was reduced and DKK1 expression was either restored and/or
markedly increased by the DNA demethylating agent 5-aza-2-
deoxycytidine (Figure 5A–B), confirming that the observed aberrant
methylation indeed was instrumental in the silencing of DKK1
expression (Figure 5B). Interestingly, 5-azacytidine has been
reported to have significant cytotoxic activity against MM cell lines
as well as patient-derived malignant plasma cells, but not against
peripheral blood mononuclear cells [49]. Of the cell lines used in
our study, OPM-1 and UM-1 display a very high sensitivity to 5-
azacytidine and treatment of these cells with this compound result
not only in promoter demethylation but also in rapid and extensive
cell death, which explains the rather modest induction of DKK1
expression. Indeed, in the LME-1 cell line, which shows a lower
sensitivity to 5-azacytidine-induced cell death, treatment results in a
much stronger upregulation of DKK1 mRNA expression. In
primary MM, we also observed dense methylation of the DKK1-
associated CpG island (Figure 4 and Figure S2). Since methylation
of the DKK1 promoter was not observed in normal bone marrow
samples [32], this methylation can be considered aberrant and
disease-related. In addition to silencing of DKK1, silencing of other
Wnt antagonists could also contribute to the enhanced Wnt
signaling in advanced MM. Consistent with this notion, Chim et
al., have reported that constitutive Wnt signaling in MM cell lines is
associated with methylation dependent silencing of several Wnt
inhibitors, including the sFRP1, 2, 4 and 5. Methylation of at least
one of these soluble Wnt inhibitors was observed in most primary
MM bone marrow samples [50].
Our finding that the DKK1 promoter is methylated and Wnt
pathway is hyperactivated in advanced multiple myeloma, strongly
suggests the presence of autocrine Wnt signaling in malignant
plasma cells. In accordance with this hypothesis we observed
inhibition of nuclear b-catenin levels and of Wnt reporter activity
upon restoration of DKK1 in MM cells (Figure 2 A–C).
Figure 5. Restoration of DKK1 expression in MM cell lines by 5-aza-2-deoxycytidine treatment. (A) DKK-1 promoter methylation analyzed
by bisulfite genomic sequencing of 10 clones, on DNA isolated from 5-aza-2-deoxycytidine treated (5-aza-CdR) and untreated (PBS) MM cell lines UM-
1 and OPM-1. Frequency of methylation was calculated by dividing the number of methylated CpG sites by the total number of analyzed CpG sites.
(B) Reverse transcriptase-PCR analysis for DKK1 gene expression in multiple myeloma cell lines in the absence and presence of the demethylating
agent 5-aza-2-deoxycytidine. b-actin expression is shown as an input control.
doi:10.1371/journal.pone.0030359.g005
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methylation of the DKK1 promoter around the transcription start
region and lack detectable DKK1 transcript (Figure 1D, Figure 3A
and Figure S1). Taken together, these data suggest that activation
of Wnt signaling in these cell lines is the consequence of DKK1
silencing and could reflect the progression-dependent Wnt
pathway activation in patients with advanced MM.
Our current study, in conjunction with work of others, points to
a multi-facetted role of DKK1 in the pathogenesis of MM. Studies
by Shaughnessy and collegues have previously also reported that
DKK1 is strongly expressed by the malignant plasma cells of most
MM patients [6]. It was shown that secretion of the DKK1 can
contribute to MM bone disease by inhibiting Wnt signaling in
osteoblasts, thereby interfering with their differentiation [14–17].
Furthermore, in line with our current findings, which suggests that
DKK1 may act as a feed-back tumor suppressor, these authors
also reported loss of DKK1 protein expression in a subgroup of
patients with advanced MM [6]. In addition to causing bone
disease, inhibition of osteoblast differentiation by DKK1 may also
promote MM growth, since mature osteoblasts can suppress
myeloma growth, whereas immature osteoblasts express high
levels of IL-6, a central growth and survival factor for myeloma
plasma cells [51]. Furthermore, DKK1 enhances the expression of
receptor activator of NF-kappa B ligand (RANKL) and downreg-
ulates the expression of osteoprotegerin (OPG) in immature
osteoblast [17]. The resulting increased RANKL/OPG ratio leads
to osteoclast activation promoting osteolytic bone disease.
Osteoclasts may also support the growth of myeloma cells through
secretion of IL-6 and osteopontin, and by adhesive interactions,
stimulating the proliferation of malignant plasma cells [52]. Thus,
like several other soluble factors expressed by MM cells, for
example vascular endothelial growth factor (VEGF) and hepato-
cyte growth factor (HGF) [53–55], DKK1 can both, exercise
paracrine effects on the BM microenvironment, and affect the
MM cells in an autocrine fashion the net effect could be either
enhanced or reduced tumor growth.
Consistent with this hypothesis, by employing a MM SCID/rab
mouse model, Yaccoby et al. showed that treatment with anti-
human DKK1-neutralizing antibody stimulates osteoblast activity,
reduces osteoclastogenesis, and promotes bone formation in
myelomatous and nonmyelomatous bones [56]. MM burden was
also reduced, but notably, not in all mice bearing human myeloma
cells [57]. Similar results were also obtained in a SCID/hu mouse
model by Fulciniti et al [56], [57]. Together, these studies suggest
that MM bone disease and tumor growth are interdependent, at
least at the intramedullary stage, and that increased bone
formation as a consequence of neutralization of DKK1, may also
control MM growth [56], [57].. However, in a 5T2MM murine
myeloma model treatment with the anti-DKK1 antibody
BHQ880 also caused a reduction of osteolytic bone lesions but
did not have any effect on tumor burden [58]. Give our current
finding that DKK1 inhibits autocrine canonical Wnt signaling in
MM cells, inhibition of DKK1 could hyperactivate the Wnt
pathway and thereby promote tumor growth, especially at
extramedullary sites. Indeed, stimulation of the Wnt signaling
pathway in a 5TGM1 mouse myeloma model significantly
increased subcutaneous tumor growth [59]. In patients, extra-
medullary growth is associated with aggressive disease, occurring
subsequent to the osteolytic bone disease, often resulting in plasma
cell leukemia. Importantly, in a human-mouse xenograft MM
model, Dutta-Simmons et al. demonstrated that the Wnt pathway
not only controls the proliferation of MM plasma cells but also
their metastatic potential [13]. Taken together, these studies
suggest a scenario in which DKK1 has a dual, stage depend, role:
whereas high DKK1 expression in early MM contributes to a
tumor permissive micronenviroment within the BM, advanced
MMs that have acquired BM independence may benefit from
DKK1 loss, which enhanced Wnt signaling and thereby promotes
MM growth and dissemination. Although blocking DKK1 inhibits
osteolytic bone disease in vivo, targeting DKK1 in MM patients
could enhance Wnt pathway activity in MM plasma cells, which
might increase the metastatic potential and extramedullary growth
of the tumor.
In conclusion, our study establishes for the first time a relation
between low or absence of DKK1 expression and the presence
Wnt pathway activation during MM progression. Moreover, we
demonstrate the presence of a functional ligand-dependent Wnt
signaling in MM cells and identify methylation of the DKK1
promoter as a mechanism underlying the absence of DKK1
expression in advanced stage MM. These data strongly suggest
that epigenetic silencing of DKK1 unleashes Wnt signaling in a
subset of advanced myelomas, promoting disease progression.
Supporting Information
Figure S1 Bisulfite genomic sequencing of the DKK1
promoter in MM cell line. Representative pictures of
immunocytochemical staining of multiple myeloma cell lines with
goat polyclonal anti-DKK1 antibody (magnification: 4006).
Prostate cancer cell line (PC-3) was used as positive control for
the DKK1 staining.
(TIF)
Figure S2 Bisulfite genomic sequencing of the DKK1
promoter in MM bone marrow samples. Bisulfite sequenc-
ing analysis was performed on DNA isolated from total bone
marrow samples of twelve MM patients (P1–P12). For individual
patient 5 clones of the DKK1 promoter region are presented. Open
circles indicate unmethylated CpG sites; closed circles represent
methylated CpG sites.
(TIF)
Table S1 Expression of Wnt family members in
345 MM patients from total therapy 2 (TT2) patients set.
(DOC)
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